title: Sustained remission including marked regression of a paravertebral plasmacytoma in a patient with heavily pretreated, relapsed multiple myeloma after treatment with bortezomib.
abstract: Despite advances in systemic and supportive therapies, multiple myeloma (MM) has remained an incurable disease, which underlines the need for novel approaches to therapy. Recent data indicate that the proteasome-inhibitor bortezomib has marked activity with manageable toxicity in relapsed and refractory MM. We here report on a patient suffering from heavily pretreated and refractory MM with a paravertebral tumor manifestation. After three cycles of bortezomib, the patient achieved near-complete remission, as well as a nearly complete regression of the paravertebral tumor. This case further documents that bortezomib is an effective novel therapy for MM.
authors.affiliation: Department of Internal Medicine I, Clinical Division of Oncology, Bone marrow transplantation and Hematology & Hemostaseology, Medical University of Vienna, Austria.
authors.forename: Maria-Theresa
authors.initials: MT
authors.lastname: Krauth
authors.forename: Alexander
authors.initials: A
authors.lastname: Bankier
authors.forename: Peter
authors.initials: P
authors.lastname: Valent
authors.forename: Peter
authors.initials: P
authors.lastname: Kalhs
authors.forename: Johannes
authors.initials: J
authors.lastname: Drach
mesh_terms: D001897:Boronic Acids / Q000627:therapeutic use*; D000069286:Bortezomib; D005260:Female; D006801:Humans; D008875:Middle Aged; D009101:Multiple Myeloma / Q000188:drug therapy*; D010954:Plasmacytoma / Q000188:drug therapy*; D011719:Pyrazines / Q000627:therapeutic use*; D012074:Remission Induction / Q000379:methods; D016879:Salvage Therapy; D013125:Spinal Neoplasms / Q000188:drug therapy*
chemical_list: D001897:Boronic Acids; D011719:Pyrazines; D000069286:Bortezomib